Literature DB >> 11547944

Spatial variability of genomic aberrations in a large glioblastoma resection specimen.

J M Kros1, P R van Run, J C Alers, C J Avezaat, T M Luider, H van Dekken.   

Abstract

In the present study, the distribution of genetic aberrations in a glioblastoma resection specimen of unusually large size (9x8x2 cm) was investigated using comparative genomic hybridization (CGH). CGH was performed on 20 samples taken from the specimen, and the genetic aberrations found were compared with the regional histology. The samples were histopathologically graded according to WHO criteria, and a division in high- and low-grade areas and infiltration rims was made. In high-grade areas, low-grade areas as well as infiltration rims, gains on 10p11.2-pter (14/20), 11q12-q22 (6/20) and losses on 4q13-qter (9/20), 10q22-qter (8/20), 11p14-pter (5/20), 13q12-qter (7/20) were revealed. Gains on 1q21-32 (2/4) and losses on 7p21-pter (3/4) were exclusively found in the high-grade areas. In the low-grade tumor samples and in the infiltration rim, gains on 16p11.2-pter (6/16), 17p11.2-pter (6/16), 17q11.2-qter (5/16), 20q11.2-q13 (3/16) and deletions on 5q31-qter (4/16) were detected. Gains on 7q21-qter (8/11) and 8q11.2-qter (6/11), and loss of chromosome 9 (4/11) and the Y-chromosome (4/11) were found in the high-grade and low-grade samples, not in the infiltration rims. The finding of a set of identical chromosomal aberrations throughout the resection specimen, most of which have been previously reported in gliomas, confirms a mechanism of clonal tumor proliferation operative in gliomas. The previously unreported genetic alterations which were predominantly traced in the tumor rims, might reflect either selection for properties related to infiltrating behavior, or genomic instability of subclones. The findings illustrate the importance of searching for high-grade genetic aberrations in low-grade tumor samples taken from cases in which sampling error is suspected.

Entities:  

Mesh:

Year:  2001        PMID: 11547944     DOI: 10.1007/s004010000327

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  5 in total

1.  Connexin 30 expression inhibits growth of human malignant gliomas but protects them against radiation therapy.

Authors:  Maria Artesi; Jerome Kroonen; Markus Bredel; Minh Nguyen-Khac; Manuel Deprez; Laurent Schoysman; Christophe Poulet; Arnab Chakravarti; Hyunsoo Kim; Denise Scholtens; Tatjana Seute; Bernard Rogister; Vincent Bours; Pierre A Robe
Journal:  Neuro Oncol       Date:  2014-08-25       Impact factor: 12.300

Review 2.  The progress of multimodal imaging combination and subregion based radiomics research of cancers.

Authors:  Luyuan Zhang; Yumin Wang; Zhouying Peng; Yuxiang Weng; Zebin Fang; Feng Xiao; Chao Zhang; Zuoxu Fan; Kaiyuan Huang; Yu Zhu; Weihong Jiang; Jian Shen; Renya Zhan
Journal:  Int J Biol Sci       Date:  2022-05-09       Impact factor: 10.750

3.  Genomic changes in progression of low-grade gliomas.

Authors:  Ahmed Idbaih; Rosana Carvalho Silva; Emmanuelle Crinière; Yannick Marie; Catherine Carpentier; Blandine Boisselier; Sophie Taillibert; Audrey Rousseau; Karima Mokhtari; François Ducray; Joelle Thillet; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  J Neurooncol       Date:  2008-07-11       Impact factor: 4.130

4.  Activation of JNK and p38 MAPK Mediated by ZDHHC17 Drives Glioblastoma Multiforme Development and Malignant Progression.

Authors:  Xueran Chen; Aijun Hao; Xian Li; Kaiqin Ye; Chenggang Zhao; Haoran Yang; Huihui Ma; Lei Hu; Zhiyang Zhao; Lizhu Hu; Fang Ye; Qiuyan Sun; Huaman Zhang; Hongzhi Wang; Xuebiao Yao; Zhiyou Fang
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

Review 5.  Radiomics and radiogenomics in gliomas: a contemporary update.

Authors:  Prateek Prasanna; Vadim Spektor; Gagandeep Singh; Sunil Manjila; Nicole Sakla; Alan True; Amr H Wardeh; Niha Beig; Anatoliy Vaysberg; John Matthews
Journal:  Br J Cancer       Date:  2021-05-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.